ValueAct's Rx for Drug Merger
You have to hand it to the folks at ValueAct Capital. The San Francisco activist hedge fund firm sure has a knack for helping companies they invest in maximize their value by finding a partner.
Stephen Taub
June 22, 2010
FILE--Eugene Melnyk speaks at the Biovail annual and special meeting of shareholders in Toronto, Wednesday, May 16, 2007. Canada's largest publicly traded pharmaceutical company, Biovail Corp., has agreed to merge with Valeant (NYSE:VRX) in a US$3.2 billion deal that will likely result in hundreds of job cuts over the next year as management works to refocus the business. THE CANADIAN PRESS/Aaron Harris
Aaron Harris
